Dabigatran
Active ingredient: Dabigatran Etexilate Mesylate
In short: Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treat
What is Dabigatran used for?
Dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.
Dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days.
Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated.
Dabigatran etexilate capsules are indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients who have undergone hip replacement surgery.
Dabigatran etexilate capsules are indicated for the treatment of venous thromboembolic events (VTE) in pediatric patients 8 to less than 18 years of age who have been treated with a parenteral anticoagulant for at least 5 days .
Dabigatran etexilate capsules are indicated to reduce the risk of recurrence of VTE in pediatric patients 8 to less than 18 years of age who have been previously treated .
⚠ Boxed warning (FDA's strongest warning)
(A) PREMATURE DISCONTINUATION OF DABIGATRAN ETEXILATE CAPSULES INCREASES THE RISK OF THROMBOTIC EVENTSPremature discontinuation of any oral anticoagulant, including dabigatran etexilate capsules, increases the risk of thrombotic events. If anticoagulation with dabigatran etexilate capsules are discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant .
(B) SPINAL/EPIDURAL HEMATOMAEpidural or spinal hematomas may occur in patients treated with dabigatran etexilate capsules who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
• use of indwelling epidural catheters • concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants • a history of traumatic or repeated epidural or spinal punctures • a history of spinal deformity or spinal surgery • optimal timing between the administration of dabigatran etexilate capsules and neuraxial procedures is not known .
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary .
Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated .
Dabigatran dosage
Dabigatran etexilate is available in different dosage forms and not all dosage forms are approved for the same indications and age groups. In addition, there are differences between the dosage forms with respect to dosing due to differences in bioavailability. Do not substitute different dosage forms on a milligram-to-milligram basis and do not combine more than one dosage form to achieve the total dose .
Indication | Dosage
Reduction in Risk of Stroke and Systemic Embolism in Non-valvular AF | CrCl > 30 mL/min: | 150 mg twice daily
CrCl 15 to 30 mL/min: | 75 mg twice daily
CrCl < 15 mL/min or on dialysis: | Dosing recommendations cannot be provided
CrCl 30 to 50 mL/min with concomitant use of P-gp inhibitors: | Reduce dosage to 75 mg twice daily if given with P-gp inhibitors dronedarone or systemic ketoconazole.
CrCl < 30 mL/min with concomitant use of P-gp inhibitors: | Avoid coadministration
Treatment of DVT and PE
Reduction in the Risk of Recurrence of DVT and PE | CrCl > 30 mL/min: | 150 mg twice daily
CrCl ≤ 30 mL/min or on dialysis: | Dosing recommendations cannot be provided
CrCl <50 mL/min with concomitant use of P-gp inhibitors: | Avoid coadministration
Prophylaxis of DVT and PE Following
Hip Replacement Surgery | CrCl > 30 mL/min: CrCl ≤ 30 mL/min or on dialysis: | 110 mg for first day, then 220 mg once daily Dosing recommendations cannot be provided
CrCl < 50 mL/min with concomitant use of P-gp inhibitors: | Avoid coadministration
Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation in Adult Patients
For patients with creatinine clearance (CrCl) >30 mL/min, the recommended dosage of dabigatran etexilate capsules is 150 mg taken orally, twice daily. For patients with severe renal impairment (CrCl 15 to 30 mL/min), the recommended dosage of dabigatran etexilate capsules is 75 mg twice daily . Dosing recommendations for patients with a CrCl < 15 mL/min or on dialysis cannot be provided.
Treatment of Deep Venous Thrombosis and Pulmonary Embolism
in Adult Patients
For patients with CrCl > 30 mL/min, the recommended dosage of dabigatran etexilate capsules is 150 mg taken orally, twice daily, after 5 to 10 days of parenteral anticoagulation. Dosing recommendations for patients with a CrCl ≤ 30 mL/min or on dialysis cannot be provided .
Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism
in Adult Patients
For patients with CrCl > 30 mL/min, the recommended dosage of dabigatran etexilate capsules is 150 mg taken orally, twice daily after previous treatment. Dosing recommendations for patients with a CrCl ≤30 mL/min or on dialysis cannot be provided . …
How to take Dabigatran — instructions & advice from the label
Advise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide).
Instructions for Patients
Tell patients to take dabigatran etexilate capsules exactly as prescribed.
Remind patients not to discontinue dabigatran etexilate capsules without talking to the healthcare provider who prescribed it.
Keep dabigatran etexilate capsules in the original bottle to protect from moisture. Do not put dabigatran etexilate capsules in pill boxes or pill organizers.
When more than one bottle is dispensed to the patient, instruct them to open only one bottle at a time.
Instruct patient to remove only one capsule from the opened bottle at the time of use. The bottle should be immediately and tightly closed.
Advise patients not to chew or break the capsules before swallowing them and not to open the capsules and take the powder alone.
Advise patients that the capsule should be taken with a full glass of water.
Bleeding
Inform patients that they may bleed more easily, may bleed longer, and should call their healthcare provider for any signs or symptoms of bleeding . …
Warnings & precautions
Do not take this medicine if: Dabigatran etexilate capsules are contraindicated in patients with:
Active pathological bleeding
History of a serious hypersensitivity reaction to dabigatran, dabigatran etexilate, or to one of the excipients of the product (e.g., anaphylactic reaction or anaphylactic shock)
Mechanical prosthetic heart valve
Premature discontinuation of any oral anticoagulant, including dabigatran etexilate, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. If dabigatran etexilate capsules are discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant and restart dabigatran etexilate capsules as soon as medically appropriate .
Dabigatran etexilate capsules increases the risk of bleeding and can cause significant and, sometimes, fatal bleeding. Promptly evaluate any signs or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue dabigatran etexilate capsules in patients with active pathological bleeding
.
Risk factors for bleeding include the concomitant use of other drugs that increase the risk of bleeding (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs). Dabigatran etexilate capsule’s anticoagulant activity and half-life are increased in patients with renal impairment
.
Reversal of Anticoagulant Effect
In adults, a specific reversal agent (idarucizumab) for dabigatran etexilate is available when reversal of the anticoagulant effect of dabigatran is needed:
For emergency surgery/urgent procedures
In life-threatening or uncontrolled bleeding
In pediatric patients, the efficacy and safety of idarucizumab have not been established. …
Dabigatran side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Increased Risk of Thrombotic Events after Premature Discontinuation
Risk of Bleeding
Spinal/Epidural Anesthesia or Puncture
Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves
Increased Risk of Thrombosis in Patients with Triple-Positive Antiphospholipid Syndrome
The most serious adverse reactions reported with dabigatran etexilate capsules were related to bleeding .
Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Adult Trials
Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation
The RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy) study provided safety information on the use of two doses of dabigatran etexilate capsules and warfarin . The numbers of patients and their exposures are described in Table 2. Limited information is presented on the 110 mg dosing arm because this dose is not approved. …
Drug interactions
The concomitant use of dabigatran etexilate capsules with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided .
P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran . Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone.
In patients with moderate renal impairment (CrCl 30 to 50 mL/min), reduce the dosage of dabigatran etexilate capsules to 75 mg twice daily when administered concomitantly with the P-gp inhibitors dronedarone or systemic ketoconazole. The use of the P-gp inhibitors verapamil, amiodarone, quinidine, clarithromycin, and ticagrelor does not require a dosage adjustment of dabigatran etexilate capsules. These results should not be extrapolated to other P-gp inhibitors [see Warnings and Precautions (5.5), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].
The concomitant use of dabigatran etexilate capsules and P-gp inhibitors in patients with severe renal impairment (CrCl 15 to 30 mL/min) should be avoided [see Warnings and Precautions (5.5), Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)]. …
About this medicine
The chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is β-Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-ethyl ester, methanesulfonate. The molecular formula is C34H41N7O5●CH4O3S and the molecular weight is 723.86 g/mol. The structural formula is:
Dabigatran etexilate mesylate is a yellow to white powder. A saturated solution in pure water has a solubility of 1.8 mg/mL. It is freely soluble in methanol, slightly soluble in ethanol, and sparingly soluble in isopropanol, very slightly soluble in acetone, practically insoluble in ethyl acetate.
Dabigatran etexilate capsules are supplied in 75 mg, 110 mg, and 150 mg strengths for oral administration. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID dd47a015-ff90-d7a7-8dcb-4e6e31a68071. Read the full official label on DailyMed.
Related medicines
Rosuvastatin Semaglutide Hydrochlorothiazide Apixaban Simvastatin Empagliflozin Furosemide Carvedilol